The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
Nixon Peabody, LLP's Products Liability Group, Boston, MA, USA.
Joseph
J
Leghorn
Elizabeth
E
Brophy
Peter
P
Rother
D000329:Advertising / Q000331:legislation & jurisprudence*; D002961:Civil Rights / Q000331:legislation & jurisprudence*; D003257:Consumer Product Safety; D018795:Device Approval / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004348:Drug Labeling / Q000266:history / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D049673:History, 20th Century; D006801:Humans; D019451:Information Management / Q000266:history / Q000331:legislation & jurisprudence; D008389:Marketing of Health Services / Q000331:legislation & jurisprudence*; D011356:Product Labeling / Q000266:history / Q000331:legislation & jurisprudence; D012586:Science / Q000331:legislation & jurisprudence; D013060:Speech; D014481:United States; D014486:United States Food and Drug Administration